| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5581772 | Clinical Lymphoma Myeloma and Leukemia | 2017 | 31 Pages |
Abstract
In routine clinical practice in France, Zarzio is mostly used as primary prophylaxis for chemotherapy-induced neutropenia in patients with hematological malignancies. Patient-related risk factors appear to have more weight in clinicians' decisions to give Zarzio than the FN risk category of the chemotherapy regimen alone in real-world practice.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Gandhi Laurent Damaj, Omar Benbrahim, Maya Hacini, Inna Voronina, Khaled Benabed, Ravaka-Fatoma Soumoudronga, Isabelle Gasnereau, Corinne Haioun, Philippe Solal-Céligny,